View the basic IMLFF stock chart on Yahoo Finance. Change the date range, chart type and compare INMED PHARMACEUTICALS INC against other. InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and. InMed Pharmaceuticals Inc. stock price, stock quotes and financial overviews from MarketWatch.
) (IMLFF InMed Inc. Pharmaceuticals
Please see disclaimer on the NetworkNewsWire website: InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed Pharmaceuticals is currently developing two products in its drug pipeline: Epidermolysis Bullosa EB is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma.
Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins or, proteins in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.
INM includes multiple cannabinoids as the active ingredients:. INM Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.
INM will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM have been selected to reduce the elevated intra-ocular pressure IOP in the affected eyes and provide neuroprotection for the retinal ganglion cells RGCs and other optic nerve tissues.
INM is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients.
We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM There are three general types of cannabinoids: Before the s, it was often speculated that cannabinoids produced their effects through nonspecific interaction with cell membranes, instead of interacting with specific receptors.
The discovery of the first cannabinoid receptors in the s helped to clarify their role. These receptors are common in animals, and have been found in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors, called CB1 and CB2. CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus.
They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are essentially absent in the medulla oblongata, the part of the brain that is responsible for respiratory and cardiovascular functions.
Thus, there is not a risk of respiratory or cardiovascular failure as there is with many other drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis. CB2 receptors are almost exclusively found in the immune system, with the greatest density in the spleen.
CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. In addition, minor variations in each receptor have been identified. There is some indication that other receptors exist, but none have been confirmed.
Cannabinoids bind reversibly and stereo-selectively to the cannabinoid receptors. The affinity of an individual cannabinoid to each receptor determines the effect of that cannabinoid.
Cannabinoids that bind more selectively to certain receptors are more desirable for medical usage. Herbal cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvents.
All herbal cannabinoids are derived from their respective 2-carboxylic acids 2-COOH by decarboxylation that is, catalyzed by heat, light, or alkaline conditions. Herbal cannabinoids occur naturally only in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichomes. In addition to cannabinoids, the resin is rich in terpenes, which are largely responsible for the odor of the cannabis plant. There are over ninety known herbal cannabinoids.
Other common cannabinoids include:. THC is the primary psychoactive component of the plant. Medically, it appears to mediate pain and to be neuroprotective. Its effects are perceived to be more cerebral. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea.
It is perceived to have more effect on the torso than on the brain or CNS. Cannabinoids were first discovered in the s. The structure of THC was first determined in Due to molecular similarity and ease of synthetic conversion, it was originally believed that CBD was a natural precursor to THC.
Cannabis plants can exhibit wide variation in the quantity and type of cannabinoids they produce. Selective breeding has been used to control the genetics of plants and modify the cannabinoid profile. For example, strains of hemp, which are used as fiber, are bred such that they are low in psychoactive chemicals like THC. Strains used in medicine are often bred for high CBD content, and strains used for recreational purposes are usually bred for high THC content, or for a specific chemical balance.
Cannabinoids can be administered by: Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat.
Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required. A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Investment Highlights Extensive portfolio of assets in dermatology, ocular disease and additional indications and cannabinoid biosynthesis Positioned to achieve value-driving, near-term corporate milestones with limited investment Led by a management team of experienced professionals capable of building value in biopharmaceuticals.
By using its comprehensive pharmaceutical and cannabinoid structures database, and by creating associations between approved pharmaceuticals whose pharmacodynamics effects are well characterized and cannabinoids with similar structures, InMed identifies active cannabinoids to act on above mentioned genes and proteins.
This type of bioinformatics assessment, as a general approach, represents significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease. INM includes multiple cannabinoids as the active ingredients: The company was founded by Christopher Bogart and International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.
Quote data, except U. Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information a does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and b shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom.
Data may be intentionally delayed pursuant to supplier requirements. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Fundamental company data and analyst estimates provided by FactSet. News InMed Pharmaceuticals Inc. Earnings Per Share TTM A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade.
To calculate, start with total shares outstanding and subtract the number of restricted shares.
InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of. Stock analysis for InMed Pharmaceuticals Inc (IMLFF:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company. InMed Pharmaceuticals (OTCQX:IMLFF) is a pre-clinical stage, fully-integrated cannabis company. Like most cannabis-derived pharma.